U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21NO4.ClH
Molecular Weight 351.825
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYCODONE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3OC

InChI

InChIKey=MUZQPDBAOYKNLO-RKXJKUSZSA-N
InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H21NO4
Molecular Weight 315.3636
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
500.0 nM [EC50]
16000.0 nM [EC50]
4000.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-6.224256E11
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-6.224256E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
19 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
22.2 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
39.3 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15.7 ng/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.9 ng/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
128.2 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
133 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
268.2 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.3 ng × h/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
99 ng × h/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
3.55 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.85 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
55%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
55%
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Co-administed with::
acetaminophen(1950 mg; single)
cocaine(1/4 g; single)
Sources:
healthy, 30 years
n = 1
Health Status: healthy
Age Group: 30 years
Sex: M
Population Size: 1
Sources:
Other AEs: Pulmonary edema...
Other AEs:
Pulmonary edema
Sources:
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 1.7%)
Dizziness (grade 1-2, 1.7%)
Abdominal pain (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Headache, Vomiting...
AEs leading to
discontinuation/dose reduction:
Headache (grade 1-2, 0.8%)
Vomiting (grade 1-2, 0.8%)
Nausea (grade 1-2, 0.8%)
Somnolence (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 6.3%)
Dizziness (grade 1-2, 4.8%)
Confusion (grade 1-2, 3.2%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Disc. AE: Vomiting, Flu syndrome...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 1-2, 0.8%)
Flu syndrome (grade 1-2, 0.8%)
Confusion (grade 1-2, 0.8%)
Fatigue (grade 1-2, 0.8%)
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
6 mg 2 times / day single, oral (mean)
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
n = 35
Health Status: healthy
Age Group: mean age 33 years
Sex: M+F
Population Size: 35
Sources:
Disc. AE: Vomiting...
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
healthy, mean age 36 years
n = 40
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.5%)
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
AEs

AEs

AESignificanceDosePopulation
Pulmonary edema
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Co-administed with::
acetaminophen(1950 mg; single)
cocaine(1/4 g; single)
Sources:
healthy, 30 years
n = 1
Health Status: healthy
Age Group: 30 years
Sex: M
Population Size: 1
Sources:
Abdominal pain grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Dizziness grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 120
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Headache grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Somnolence grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral (mean)
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 125
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 125
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Confusion grade 1-2, 3.2%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Dizziness grade 1-2, 4.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Nausea grade 1-2, 6.3%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 63
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 63
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Confusion grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Fatigue grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Flu syndrome grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
unhealthy, adult
n = 126
Health Status: unhealthy
Condition: chronic pain
Age Group: adult
Sex: M+F
Population Size: 126
Sources: Page: /nda/98/20932_medr_P2.pdf - p.21
Vomiting 11.4%
Disc. AE
6 mg 2 times / day single, oral (mean)
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
n = 35
Health Status: healthy
Age Group: mean age 33 years
Sex: M+F
Population Size: 35
Sources:
Vomiting 2.5%
Disc. AE
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
healthy, mean age 36 years
n = 40
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Population Size: 40
Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
yes
yes
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Page: 7.0
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Tox targets
PubMed

PubMed

TitleDatePubMed
Time-release analgesic drug causes fatal overdoses in United States.
2001 Aug
"No, Duke. No divorce".
2001 Aug 20
Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital.
2001 Dec
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
2001 Feb
Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.
2001 Feb
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
2001 Feb
The potent perils of a miracle drug.
2001 Jan 8
Federal reports say oxycodone abuse is on the rise.
2001 Jul 1
Profits vs. pain relief.
2001 Jul 2
'Not an appropriate use'. Did the makers of OxyContin push too hard?
2001 Jul 2
Addressing OxyContin abuse.
2001 Jul-Aug
Preoperative diclofenac is a useful adjunct to spinal anesthesia for day-case varicose vein repair.
2001 Jul-Aug
Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine.
2001 Jul-Aug
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration.
2001 Mar
Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.
2001 May
The antinociceptive and sedative effects of carbachol and oxycodone administered into brainstem pontine reticular formation and spinal subarachnoid space in rats.
2001 May
Painkiller crackdown.
2001 May 14
[Treatment of pain in cancer with systemically administered opioids].
2001 May 19
Conversion ratio and cost of oxycodone.
2001 May-Jun
OxyContin, the media, and law enforcement.
2001 May-Jun
The use of oxycodone in cancer-related pain: a literature review.
2001 Nov
Clinical case study.
2001 Nov-Dec
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Opioid therapy for chronic painful conditions.
2001 Oct
States respond to growing abuse of painkiller.
2001 Oct-Nov
Managing postoperative pain.
2001 Sep
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine.
2001 Sep
Oxycodone and oxycontin.
2001 Sep 17
Oxycodone/ibuprofen.
2002
The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid.
2002 Apr
Capillary electrophoresis and capillary electrophoresis-ion trap multiple-stage mass spectrometry for the differentiation and identification of oxycodone and its major metabolites in human urine.
2002 Apr 25
Severe chronic renal failure in association with oxycodone addiction: a new form of fibrillary glomerulopathy.
2002 Aug
Minimal interaction between gatifloxacin and oxycodone.
2002 Aug
Nasal administration of opioids for pain management in adults.
2002 Aug
The influence of anaesthesia and surgery on the circadian rhythm of melatonin.
2002 Jan
A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma.
2002 Jan
Safety and efficacy of controlled-release oxycodone: a systematic literature review.
2002 Jul
OxyContin and neonatal abstinence syndrome.
2002 Jun
There is no accounting for accountability.
2002 Mar
From physician to inmate.
2002 May
Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory laparoscopic tubal ligation surgery.
2002 May
Venous malformations associated with central pain: report of a case.
2002 Nov
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.
2002 Oct
Detection of cocaine analytes and opiates in nails from postmortem cases.
2002 Oct
Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases.
2002 Oct
Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy.
2002 Oct
Massive OxyContin ingestion refractory to naloxone therapy.
2002 Oct
Interscalene brachial plexus block is superior to subacromial bursa block after arthroscopic shoulder surgery.
2002 Sep
Review: tricyclic antidepressants, capsaicin, gabapentin, and oxycodone are effective for postherpetic neuralgia.
2002 Sep-Oct
Oxycontin--misuse and abuse.
2002 Summer
Patents

Sample Use Guides

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.
Route of Administration: Oral
Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:06:11 UTC 2022
Edited
by admin
on Fri Dec 16 16:06:11 UTC 2022
Record UNII
C1ENJ2TE6C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYCODONE HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
OXYCODONE HYDROCHLORIDE [USAN]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF XARTEMIS
Brand Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF OXYCET
Common Name English
ROXIPRIN COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE [MI]
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, HYDROCHLORIDE, (5.ALPHA.)-
Systematic Name English
OXYCODONE HYDROCHLORIDE CII [USP-RS]
Common Name English
OXYCODONE HYDROCHLORIDE [MART.]
Common Name English
COMBUNOX COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF TARGINIQ
Brand Name English
4,5?-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride
Systematic Name English
OXYCET COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
ANHYDROUS OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF ROXILOX
Common Name English
TROXYCA COMPONENT OXYCODONE HYDROCHLORIDE
Brand Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF ROXIPRIN
Common Name English
OXYCODONE HYDROCHLORIDE [VANDF]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF TYLOX
Common Name English
TARGINIQ COMPONENT OXYCODONE HYDROCHLORIDE
Brand Name English
OXECTA
Brand Name English
OXYCODONE HCL
Common Name English
CODOXY COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF PERCODAN
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF PERCODAN-DEMI
Common Name English
PERCODAN-DEMI COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF COMBUNOX
Common Name English
PERCODAN COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
Oxycodone hydrochloride [WHO-DD]
Common Name English
XARTEMIS COMPONENT OXYCODONE HYDROCHLORIDE
Brand Name English
ROXICET COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCONTIN
Brand Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF ROXICET
Common Name English
ROXICODONE
Brand Name English
PERCOCET COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF CODOXY
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF TROXYCA
Brand Name English
ROXYBOND
Brand Name English
ENDOCODONE
Brand Name English
TYLOX COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
ROXILOX COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE CII
USP-RS  
Common Name English
OXYCODONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
OXYCODONE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF PERCOCET
Common Name English
Classification Tree Code System Code
DEA NO. 9143
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
NCI_THESAURUS C67413
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
NCI_THESAURUS C1506
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
Code System Code Type Description
CHEBI
7859
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
NCI_THESAURUS
C48010
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
CAS
124-90-3
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
FDA UNII
C1ENJ2TE6C
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
PUBCHEM
5462350
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
RXCUI
82063
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY RxNorm
RS_ITEM_NUM
1485205
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
EVMPD
SUB03583MIG
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
EPA CompTox
DTXSID80924674
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
DAILYMED
C1ENJ2TE6C
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
ECHA (EC/EINECS)
204-717-1
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
MERCK INDEX
M8328
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY Merck Index
ChEMBL
CHEMBL656
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
DRUG BANK
DBSALT000277
Created by admin on Fri Dec 16 16:06:11 UTC 2022 , Edited by admin on Fri Dec 16 16:06:11 UTC 2022
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities D and E: not more than 10 times the area of the peak due to oxycodone in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
sum of impurities D and E: not more than 10 times the area of the peak due to oxycodone in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY